USSTOCK.TODAY
Market Closed
Log in Sign up

Quoin Pharmaceuticals Ltd ADR(QNRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

QNRX
QNRX
Quoin Pharmaceuticals Ltd ADR
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$3.35
-0.21 ▼ -5.90%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$3.36
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -9.14Insider Own ⓘ -Shs Outstand ⓘ 4.8MPerf Week ⓘ -10.67%
Market Cap ⓘ 0.02BForward P/E ⓘ -EPS next Y ⓘ 53.05%Insider Trans ⓘ -Shs Float ⓘ -Perf Month ⓘ -16.04%
Enterprise Value ⓘ -0.02BPEG ⓘ -EPS next Q ⓘ -0.91Inst Own ⓘ 58.09%Short Float ⓘ -Perf Quarter ⓘ -39.86%
Income ⓘ -0.02BP/S ⓘ -EPS this Y ⓘ 65.17%Inst Trans ⓘ 3.59%Short Ratio ⓘ 0.04Perf Half Y ⓘ -30.93%
Sales ⓘ 0.00BP/B ⓘ 0.56EPS next 5Y ⓘ 52.46%ROA ⓘ -95.47%Short Interest ⓘ 0.02MPerf YTD ⓘ -76.78%
Book/sh ⓘ 5.97P/C ⓘ 0.48EPS past 3/5Y ⓘ 2.37% 61.71%ROE ⓘ -143.02%52W High ⓘ -85.74% ($23.50)Perf Year ⓘ -81.57%
Cash/sh ⓘ 6.91P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -68.48%52W Low ⓘ 3.08% ($3.25)Perf 3Y ⓘ -97.85%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 98.98%Gross Margin ⓘ -Volatility(W/M) ⓘ 7.87% 7.37%Perf 5Y ⓘ -99.99%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.32Perf 10Y ⓘ -100%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 7.2EPS Q/Q ⓘ 85.8%Profit Margin ⓘ -RSI (14) ⓘ 33.86Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 7.2Sales Q/Q ⓘ -SMA20 ⓘ -13.02% ($3.85)Beta ⓘ 1.66Target Price ⓘ $21.57
Payout ⓘ -Debt/Eq ⓘ 0Earnings ⓘ 2026/11/5SMA50 ⓘ -28.85% ($4.71)Rel Volume ⓘ 0.02Prev Close ⓘ $3.56
Employees ⓘ 4LT Debt/Eq ⓘ 0EPS/Sales Surpr. ⓘ 36% -SMA200 ⓘ -40.99% ($5.68)Avg Volume(3M) ⓘ 0.53MPrice ⓘ $3.35
IPO ⓘ 2016/7/29Option/Short ⓘ No/YesTrades ⓘ 132Volume ⓘ 11,055Change ⓘ -5.9%
Company
QNRX QNRXQuoin Pharmaceuticals Ltd ADR | NASD | Biotechnology Deep dive

Crown Pharmaceuticals () is a late-stage clinical specialty pharmaceutical company focused on rare and underserved skin diseases. Its lead candidate, QRX003, is a topical lotion developed to treat Netherton Syndrome, a condition caused by a deficiency of the LEKTI protein. QRX003 has secured designations from both the U.S. FDA and the European EMA as an orphan drug, as well as an FDA Rare Pediatric Disease designation, and two pivotal trials for systemic application are currently underway, making it a small-cap dermatology biotech.

Quote

Over the past 1 year, on the lower side

86% below its 1-year high.

Now $3.35
52w low$3.2552w high$23.50
52W Range0%
Volume ⓘ 11,055

Traded less than usual. That is 2% of its average volume.

C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for valuation, dividends, or not applicable.
ETFs holding this stock 1 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #469 of 598 in the industry

Based on market cap of $16M.

FAQ

FAQ

What kind of company is QNRX?

QNRX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of QNRX?

The market cap of QNRX is approximately $16M, ranking 5,219 within its sector.

What is the 52-week high and low for QNRX?

QNRX has recorded a 52-week high of $23.50 and a low of $3.25.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels